A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)
James R. Berenson(Oncotherapeutics (United States)), Robert Vescio(Royal Adelaide Hospital), Daisy Martinez(Oncotherapeutics (United States)), Regina A. Swift(Institute for Myeloma & Bone Cancer Research), Shahrooz Eshaghian(Cedars-Sinai Medical Center), D. Greenwald, Youram Nassir, Benjamin Eades(James Madison University), Tanya M. Spektor(Oncotherapeutics (United States)), Carley Turner(Oncotherapeutics (United States)), Ravindranath Patel(Comprehensive Blood & Cancer Center), Alberto Bessudo(California Cancer Associates for Research and Excellence), Robert A. Moss(Pfizer (United States)), A.J. Munayco Sánchez(Oncotherapeutics (United States)), Stephen Lim(Cedars-Sinai Medical Center), Ralph V. Boccia(Center for Cancer and Blood Disorders), Gary K. Schwartz(Baylor University Medical Center), Jennifer To(Oncotherapeutics (United States)), Laura V. Stampleman
Cited by 2
Related Papers
Tumour exosome integrins determine organotropic metastasis
|Nature|2015|5.2k
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
|Journal of Clinical Oncology|2005|1.1k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
|Nature Genetics|2010|725